Sirtris Pharmaceuticals

Latest Headlines

Latest Headlines

UPDATED: GSK moves to shutter Sirtris' Cambridge office, integrate R&D

GlaxoSmithKline has decided to shutter Sirtris Pharmaceutical's office in Cambridge, MA, opting to fully integrate their research work now underway into the giant pharma company's R&D operations.

Sirtris co-founder fires back against resveratrol critics

David Sinclair and his allies believe he has scored a major victory in the controversial--and complex--field of anti-aging science. With a new research paper, the Harvard genetics professor shows how the red wine chemical resveratrol and other compounds directly activate an enzyme called SIRT1, an activity on the target that has been hotly contested.

OvaScience grabs $37M B round for fertility treatments

OvaScience, which is focused on developing fertility treatments based on stem cell discoveries, landed a $37 million Series B round of funding.

Upstart Verastem challenges Wall Street with puzzling $50M IPO

Just a few months ago Christoph Westphal's new biotech, Verastem, raised a hefty $32 million Series B round based on the promise of the developer's cancer stem cell technology and a trio of noted

New study debunks longevity link for GSK's sexy sirtuins

Those sexy "fountain of youth" studies on sirtuins that grabbed headlines around the world and helped spur GlaxoSmithKline to spend $720 million to snap up Sirtris at an early development stage have

GSK-owned Sirtris drug extends lives of obese mice

After biotech Sirtris' anti-aging science took a shelling in recent years, one of the firm's drugs that mimics the red wine chemical resveratrol showed in a new study that it could extend the average

Weak efficacy, renal risks force GSK to dump a resveratrol program

GlaxoSmithKline is dumping its program for SRT501, a special formulation of resveratrol which the pharma company scooped up in the $720 million buyout of Sirtris in 2008. GSK suspended a Phase IIa

GSK orders Sirtris execs to stop selling resveratrol

GlaxoSmithKline (NYSE: GSK) has ordered two Sirtris executives--Christoph Westphal and Michelle Dipp--to stop selling a resveratrol dietary supplement based on the drug the two companies have in

Glaxo spurns new research raising doubts about resveratrol

Over the past few years resveratrol has emerged as one of the most closely-tracked development programs in biotechnology. GlaxoSmithKline paid $720 million to buy Sirtris Pharmaceuticals back in 2007

Mass. biotechs ripe for buyouts

Recently, GSK forked over $720 million for Sirtris Pharmaceuticals and Japan's Takeda made an